



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. AM100056 D1)

In re Patent Application of:) Appln. No.: 10/618,044
DAN M. BERGER *et al.*) Confirmation No.: 4109
Filed: 07/10/2003) Customer No.: 25291
For: TRICYCLIC PROTEIN) Group Art Unit: 1626
KINASE INHIBITORS) Examiner: Ebenezer O. Sackey
) Paper No.: 13
)

TRANSMITTAL LETTER

Dear Sir:

Transmitted herewith in the above-referenced patent application is an Amendment with an attachment. It is believed that no additional fee is required.

Thank you for your attention to this matter.

Respectfully submitted,

WYETH

Date: September 15, 2005

By: Anne M. Rosenblum
Anne M. Rosenblum
Attorney for Applicants
Registration No. 30,419

FILING BY EXPRESS MAIL UNDER 37 C.F.R. § 1.10

This correspondence and the accompanying documents identified hereinabove are being deposited with the U.S. Postal Service on September 15, 2005 to be delivered by the "Express Mail Post Office to Addressee" service under Mailing Label Number ED 831331239 US addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Anne M. Rosenblum
Anne M. Rosenblum



916-05

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. AM100056 D1)

In re Patent Application of:) Appln. No.: 10/618,044
DAN M. BERGER *et al.*) Confirmation No.: 4109
Filed: 07/10/2003) Customer No.: 25291
For: TRICYCLIC PROTEIN) Group Art Unit: 1626
KINASE INHIBITORS) Examiner: Ebenezer O. Sackey
) Paper No.: 13
)

AMENDMENT

Dear Sir:

Responsive to the Office communication mailed June 15, 2005 in the above-referenced patent application, please amend the above-referenced application using the below instructions.

REMARKS

Reconsideration of this application, as amended, is respectfully requested.

In accord with 37 C.F.R. § 1.121, the amendment to the claims and a complete listing of all pending claims in the application begin on a separate sheet. For the convenience of the Office staff, the amendment is placed in the below Appendix and incorporated herein by reference thereto. The amendment adds no new matter into the application.

The present amendment responds to the Office action and corrects certain obvious typographical or clerical errors that recently came to light. In particular, it was noticed that R₆ is defined in Claim 1 as being alkenyl of 2-6 carbon atoms or alkynyl of 2-6 carbon atoms whereas the proviso inadvertently referred to the alkenyl and alkynyl substituents in the R₆ position as having 2-7 carbon atoms. To be consistent with the definition of R₆, the obvious typographical or clerical error in the proviso is being corrected (page 10 of the amendment).

At the outset, it is gratefully acknowledged that the Examiner allowed Claims 1, 10, 19 and 20. Applicants also greatly appreciate the Examiner's kind indication of how they can put the case in condition for allowance, *i.e.*, combine Claims 22 and 23; and cancel Claims 32 and 33. As will be explained in more detail below, Applicants complied in part but, for reasons given herein, it is hoped that the Examiner will be persuaded to allow the case despite the inclusion of Claims 32 and 33 in the pending claims.

Page 1 of 26